Micrograph News and Research

RSS

New mouse model demonstrates clear differences in virulence among mpox virus clades

Scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health have removed a major roadblock to better understanding of mpox (formerly, monkeypox).

14 Feb 2023

Experimental vaccine completely protects cynomolgus macaques against lethal Sudan virus

A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine.

3 Feb 2023

Experimental vaccine against Marburg virus shows promise in first-in-human clinical trial

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

30 Jan 2023

Investigational vaccine regimen safe but did not provide protection against HIV acquisition

An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined.

18 Jan 2023

Randomized trials demonstrate the safety of Ebola vaccine regimens in adults and children

Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups, according to results published today in the New England Journal of Medicine.

15 Dec 2022

NIAID awards more than $12 million for the development of antiviral therapies

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.

21 Nov 2022

Study illuminates how a typical gut bacterium spreads through the body

A typical gut bacterium that can spread through the body and cause a serious infection resists natural immune defenses and antibiotics by enhancing its protective outer layer, known as the cell envelope, according to a new study by Weill Cornell Medicine investigators.

10 Nov 2022

Research sheds light on specific protein interaction that could provide new treatment strategy to combat Cholera

Bacterial infectious diseases are still a huge contributor to global disease burden and with antibiotic resistance on the rise worldwide there is an urgent need for novel treatment strategies against bacteria.

14 Oct 2022

Clinical trial to evaluate antiviral drug for monkeypox begins in the Democratic Republic of the Congo

A clinical trial to evaluate the antiviral drug tecovirimat, also known as TPOXX, in adults and children with monkeypox has begun in the Democratic Republic of the Congo (DRC).

12 Oct 2022

Clinical trial to test the safety, efficacy of bacteriophages for treating P. aeruginosa infections in CF patients

Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs and other organs in the body.

11 Oct 2022

Impaired immune responses not responsible for COVID-19 rebound, findings suggest

Findings from a small study of eight patients published in Clinical Infectious Diseases suggest that COVID-19 rebound is likely not caused by impaired immune responses.

6 Oct 2022

UW Medicine researchers seek participants for Phase 3 clinical trial of a drug to treat monkeypox

UW Medicine researchers are recruiting participants for a Phase 3 clinical trial of a drug to treat the monkeypox virus.

16 Sep 2022

New method evaluates how mutations to SARS-CoV-2 can affect antibody recognition in rapid antigen tests

A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.

15 Sep 2022

Phase 3 clinical trial commences to evaluate antiviral for monkeypox

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States.

9 Sep 2022

NIH issues funding opportunities to support the development of new COVID-19 diagnostics

The National Institutes of Health has issued two new funding opportunities for diagnostic test manufacturers to develop the next generation of COVID-19 tests, with a major focus on accessibility.

8 Sep 2022

Clinical trial begins evaluating alternative strategies to administer the JYNNEOS monkeypox vaccine

A clinical trial evaluating alternative strategies for administering the JYNNEOS monkeypox vaccine to increase the number of available doses has begun enrolling adult volunteers.

8 Sep 2022

SARS-CoV-2 antigen levels associated with COVID-19 severity and other clinical outcomes

The amount of SARS-CoV-2 antigen measured in the blood of patients hospitalized with COVID-19 is associated with illness severity and other clinical outcomes, according to a new study published in the Annals of Internal Medicine.

29 Aug 2022

NIH experts discuss a published case series detailing the symptoms and outcomes of monkeypox

Lessons learned from the public health responses to the HIV and COVID-19 pandemics should help guide the response to the current outbreak of monkeypox, National Institutes of Health experts write in an editorial published today in the New England Journal of Medicine.

25 Aug 2022

Monkeypox can persist in household environments, according to CDC study

Researchers assess the viability and viral load of MPXV on household objects and surfaces.

15 Aug 2022

Mitochondrial DNA mutations are associated with an increased risk of atherosclerosis

Mitochondria are organelles found within most cells, best known for generating the chemical energy required to power cellular functions.

4 Aug 2022